• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Driving the Speed of Adoption with Decentralized Clinical Trials

News
Article

Sponsored Content

Biopharma companies and contract research organizations (CROs) adopted decentralized or digital clinical trials (DCTs) to reduce contact, improve the patient experience and keep studies on track during the pandemic. It’s already clear that the virtual approach of DCTs are benefiting life science organizations. From improvements in clinical trial operations such as enhanced patient engagement and site experience to cost savings and better data integration, the clinical trial dynamic has shifted and supports DCTs as a legitimate way to execute studies.

Related Content